Financial Performance - The company's operating revenue for 2022 was ¥195,252,385.91, representing a 26.96% increase compared to ¥153,785,686.53 in 2021[22]. - The net profit attributable to shareholders for 2022 was ¥35,891,785.18, a decrease of 19.73% from ¥44,733,830.57 in 2021[22]. - Basic and diluted earnings per share for 2022 were both ¥0.54, down 31.65% from ¥0.79 in 2021[22]. - The company's total revenue for Q1 2022 was approximately ¥37.27 million, Q2 was ¥57.75 million, Q3 was ¥44.23 million, and Q4 was ¥56.00 million, indicating a strong performance in Q2[29]. - The net profit attributable to shareholders for Q1 2022 was ¥7.17 million, Q2 was ¥14.07 million, Q3 was ¥8.88 million, and Q4 was ¥5.77 million, showing fluctuations throughout the year[29]. - The company achieved operating revenue of 195.25 million yuan, a year-on-year increase of 26.96%[68]. - Net profit attributable to shareholders decreased by 19.73% to 35.89 million yuan, while net profit excluding non-recurring gains and losses increased by 2.67% to 23.94 million yuan[68]. - The company's revenue from implantable medical devices reached ¥189,452,993.26, accounting for 97.03% of total revenue, with a year-on-year growth of 28.35%[94]. - Revenue from overseas markets grew significantly by 62.51% to ¥35,976,735.68, representing 18.43% of total revenue[94]. Cash Flow and Investments - The net cash flow from operating activities decreased by 27.37% to ¥48,309,238.18 in 2022 from ¥66,510,692.29 in 2021[22]. - The company achieved a significant increase in cash and cash equivalents, totaling ¥34,605,263.28, a 2668.07% increase compared to a negative balance of ¥1,347,522.06 in the previous year[91]. - The total cash inflow from investment activities increased by 29.79% to ¥1,137,133,331.73 in 2022, while cash outflow decreased by 6.09% to ¥1,118,580,582.99[111]. - The net cash flow from investment activities turned positive at ¥18,552,748.74, a significant improvement of 105.89% from a negative ¥314,931,962.09 in the previous year[111]. - Investment income contributed ¥8,792,273.20, accounting for 22.00% of the total profit, primarily from returns on financial products[114]. - The total investment amount for 2022 was ¥227,169,646.05, representing a decrease of 39.84% from ¥375,571,502.73 in the previous year[120]. Research and Development - The company reported a significant focus on R&D in new medical technologies, particularly in the field of bio-materials and 3D printing applications for medical devices[14]. - The company’s R&D investment for 2022 was ¥40,572,232.74, a slight decrease of 2.61% from ¥41,658,606.43 in the previous year[91]. - The number of R&D personnel increased to 70 in 2022, representing an 18.64% growth from 59 in 2021[106]. - The company has developed multiple innovative products based on advanced manufacturing technologies, including bio-additive manufacturing and digital design[78]. - Clinical trials are ongoing for the absorbable multilayer fiber hemostatic product, which aims to enhance the company's offerings in the hemostatic product category[106]. Market Expansion and Product Development - The company is expanding its market presence with new product lines in cranio-maxillofacial repair systems, targeting both domestic and international markets[15]. - The company has successfully won bids for its "artificial dura mater patch" in four provinces, including Jiangsu, Shandong, Fujian, and Anhui, as part of a centralized procurement initiative[45]. - The craniofacial repair system, based on PEEK material, is one of the few domestic products designed for craniofacial defect repair, with significant market potential as it replaces traditional titanium materials[53]. - The company aims to strengthen its competitive advantage in the domestic market while enhancing its international market expansion efforts[74]. - The company plans to extend its technology platform applications to oral and other surgical fields, developing new product lines such as hemostatic agents and medical adhesives[130]. Governance and Management - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements[149]. - The company has established a performance evaluation and incentive mechanism for its senior management, ensuring transparency in the hiring process[150]. - The company maintains a complete and independent business operation, with no interference from controlling shareholders[152]. - The company has a robust financial independence, with a separate financial accounting system and no shared bank accounts with controlling shareholders[156]. - The company has a well-defined governance structure that promotes the protection of minority shareholders' rights[147]. Challenges and Risks - The company faces risks related to new product development and technological iteration, which could impact its market competitiveness if not addressed[138]. - Regulatory changes, such as national healthcare policies, pose risks that the company must navigate to maintain operational stability[139]. - Increased competition in the neurosurgical high-value medical consumables market necessitates continuous improvement in product development and marketing strategies[141]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 20% to 1.44 billion RMB, driven by new product launches and market expansion[171]. - The company plans to enhance its marketing capabilities by leveraging existing product advantages and participating in centralized procurement opportunities, aiming to increase brand influence and market penetration[132]. - A strategic acquisition of a local biotech firm is expected to enhance the company's product portfolio and accelerate growth in regenerative medicine[171].

Financial Performance - The company's operating revenue for Q1 2023 was ¥44,485,769.60, representing a 19.35% increase compared to ¥37,272,422.06 in the same period last year[6]. - Net profit attributable to shareholders for Q1 2023 was ¥7,816,548.85, up 9.19% from ¥7,165,807.56 in Q1 2022[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,454,127.50, a significant increase of 49.78% from ¥4,309,093.61 in the previous year[6]. - Basic and diluted earnings per share for Q1 2023 were both ¥0.12, reflecting a 9.09% increase from ¥0.11 in the same quarter last year[6]. - The total operating revenue for the first quarter was CNY 44,485,769.60, an increase of 19.5% compared to CNY 37,272,422.06 in the previous period[28]. - The net profit for the first quarter reached CNY 7,816,548.85, representing a 9.3% increase from CNY 7,149,462.11 in the same period last year[29]. Cash Flow and Liquidity - The net cash flow from operating activities reached ¥19,434,599.35, a remarkable increase of 925.83% compared to a negative cash flow of ¥2,353,328.55 in Q1 2022[6]. - Operating cash flow net amount reached ¥19,434,599.35, a significant improvement from a negative ¥2,353,328.55 in the previous period, indicating a strong recovery in operational performance[33]. - Total cash inflow from operating activities was ¥66,508,610.90, compared to ¥45,011,097.35 in the prior period, reflecting a year-over-year increase of approximately 47.9%[33]. - Cash outflow from operating activities totaled ¥47,074,011.55, slightly decreased from ¥47,364,425.90, showing effective cost management[33]. - The cash and cash equivalents at the end of the period stood at ¥12,837,726.43, down from ¥8,156,838.16, indicating a decrease in liquidity[35]. - The total cash flow from operating, investing, and financing activities resulted in a net decrease of ¥31,925,042.71, compared to a decrease of ¥2,000,667.70 in the prior period, indicating overall cash management challenges[35]. Assets and Liabilities - Total assets at the end of Q1 2023 were ¥728,447,431.74, a decrease of 2.21% from ¥744,919,499.58 at the end of the previous year[6]. - The total liabilities decreased to CNY 118,048,593.35 from CNY 142,337,210.04 in the prior period[27]. - The company reported an increase in other receivables from ¥1,326,619.54 to ¥3,362,187.29 during the reporting period[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,460[16]. - The top two shareholders, Yuan Yuyu and Xu Tao, each hold 16.53% of the shares, totaling 10,922,547 shares[16]. - The top ten unrestricted shareholders hold a total of 11,362,136 shares, representing significant ownership concentration[16]. - The company has a pledge of 3,060,000 shares by shareholder Yuan Yuyu[16]. Government Subsidies and Non-Recurring Gains - The company received government subsidies amounting to ¥695,663.75 during the quarter, contributing to the increase in net profit[12]. - The company reported a total of ¥1,362,421.35 in non-recurring gains for the quarter, after accounting for tax effects[12]. - The significant increase in net cash flow was primarily due to revenue growth and receipt of government subsidies[15]. Research and Development - Research and development expenses were CNY 5,661,139.07, remaining stable compared to CNY 5,619,822.65 in the previous period[28]. - The company has successfully registered four new medical devices, including "hard meninges medical glue" and "titanium screws for craniofacial fixation," all classified as Class III medical devices[22]. Future Plans - The company plans to expand its market presence and invest in new technologies to drive future growth[29]. - The company has not disclosed any new strategies related to market expansion or mergers and acquisitions in the current report[21].

关于举办 2022 年度网上业绩说明会的公告 证券代码：301033 证券简称：迈普医学 公告编号：2023-019 广州迈普再生医学科技股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 广州迈普再生医学科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。为便于广大投资者更加全面深入地了解公司经营 业绩、发展战略等情况，公司定于 2023 年 5 月 5 日（星期五） 15:00-16:00 在"价值在线"（www.ir-online.cn）举办 2022 年度 网上业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见 和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 5 月 5 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 董事长、总经理袁玉宇先生 关于举办 2022 年度网上业绩说明会的公 ...

证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2021002 | --- | --- | --- | --- | |------------|----------------------------------|----------------------|------------| | | | | | | 投资者关 | ☑ 特定对象调研 | ☐ 分析师会议 | ☐ 媒体采访 | | 系活动类 | ☐ 业绩说明会 | ☐ 新闻发布会 | ☐ 路演活动 | | 别 | ☑ 现场参观 | ☐ 一对一沟通 | ☐ 其他 | | | 天风证券 张雪 | | | | | 上投摩根 蔡云翔 | | | | 参与单位 | 招商资管 徐文 | | | | 名称及人 | 德邦资管 郝晓婧 | | | | 员姓名 | 互兴资本 刘家将 | | | | | 东盈投资 皮熙龙、张嘉敏 | | | | 时间 2021 | 年 11 月 16 | 日下午 14:00-16:00 | | | | 地点 公司会议室及公司展厅 | | | | | 董事长、总经理：袁玉宇 | | | ...

编号：2021003 证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------|---------------------------------------------------------------------|---------------------------|------------| | | | | | | 投资者关 | ☑ 特定对象调研 | ☐ 分析师会议 | ☐ 媒体采访 | | 系活动类 | ☐ 业绩说明会 | ☐ 新闻发布会 | ☐ 路演活动 | | 别 | ☑ 现场参观 | ☐ 一对一沟通 | ☐ 其他 | | | 2021 年 11 月 23 日 | | | | | 中泰证券：孙宇瑶；圆信永丰：方瑾； | | | | | 敦和资管：林天成；景领投资：张轶伦 | | | | 参与单位 | 2021 年 11 月 24 日 | | | | 名称及人 | 华安证券：谭国超；长城基金：梁福睿； | | | | 员姓名 | 信达澳银：李点典；创金合信：毛丁丁、王鑫； | | ...

投资者关系活动记录表 证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 编号：2021001 | --- | --- | --- | --- | |------------|-------------------------------------|--------------|------------| | | | | | | 投资者关 | ☑ 特定对象调研 | ☐ 分析师会议 | ☐ 媒体采访 | | 系活动类 | ☐ 业绩说明会 | ☐ 新闻发布会 | ☐ 路演活动 | | 别 | ☑ 现场参观 | ☐ 一对一沟通 | ☐ 其他 | | | 广发基金：吴兴武、梁东旭 | | | | | 东方证券资管：江琦、刘中群 | | | | 参与单位 | 华泰联合证券：孔垂岩 | | | | 名称及人 | 国泰基金：任一林 | | | | 员姓名 | 中科沃土基金：孟禄程 理成资产：周锐 | | | | | 天贝合资产：王海剑 | | | | 时间 2021 | 年 11 月 3 日下午 | 14:00-17:00 | | | | 地点 公司会议室及公司展厅 | | | | | 董事长、 ...

编号：2021004 证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------|-------------------------------------------------|-------------------------------------------------| | | | | | 投资者关 | ☑ 特定对象调研 | 分析师会议 ☐ 媒体采访 | | 系活动类 | ☐ 业绩说明会 | ☐ 路演活动 | | 别 | ☑ 现场参观 | ☑ 其他：电话会议 | | | 2021 年 12 月 14 日（电话会议） | | | | 方正医药：唐爱金、王美麒； 中信保诚基金：王岩； | | | | | 中信建投资管：彭国宇； 中金基金：张羽、丁天宇； | | | 兴证全球基金：隋毅； 华宝基金：杜舟； | | | | 天弘基金：周瓅、宋鹏； | 方正证券：倪仲鑫、翟伟； | | | 盈峰资本：张林飞； | 碧云银霞投资：周伊莎； | | | 银河基金：牟方晓； 国融自营：赵小小； | | | 参与 ...

证券代码：301033 证券简称：迈普医学 广州迈普再生医学科技股份有限公司 投资者关系活动记录表 编号：2022002 | --- | --- | --- | --- | |----------|------------------------------------------------------------------|---------------------------------|------------| | | | | | | 投资者关 | ☑ 特定对象调研 | ☐ 分析师会议 | ☐ 媒体采访 | | 系活动类 | ☐ 业绩说明会 | ☐ 新闻发布会 | ☐ 路演活动 | | 别 | ☑ 现场参观 | ☐ 一对一沟通 | ☐ 其他 | | | 2022 年 7 月 5 日 | | | | | 天风证券：张雪、钟南 | | | | | 东方阿尔法基金：程可 | | | | 参与单位 | 正圆私募基金：钟晓琳 | | | | 名称及人 | 宁波梅山保税港区圆合资本：陈家华 | | | | 员姓名 | 2022 年 7 月 7 日 中泰证券：于佳喜 天虫资本 ：许佳瑛 | | | | 时间 | ...